Dirmesropian S, Wood J G, MacIntyre C R, Newall A T
a School of Public Health and Community Medicine; UNSW Australia ; Sydney , NSW Australia.
Hum Vaccin Immunother. 2015;11(4):818-25. doi: 10.1080/21645515.2015.1011954.
The 13-valent pneumococcal conjugated vaccine (PCV13) is already recommended for some adult groups and is being considered for wider use in many countries. In order to identify the strengths and limitations of the existing economic evaluation studies of PCV13 in adults and the elderly a literature review was conducted. The majority of the studies identified (9 out of 10) found that PCV13 was cost-effective in adults and/or the elderly. However, these results were based on assumptions that could not always be informed by robust evidence. Key uncertainties included the efficacy of PCV13 against non-invasive pneumonia and the herd immunity effect of childhood vaccination programs. Emerging trial evidence on PCV13 in adults from the Netherlands offers the ability to parameterize future economic evaluations with empirical efficacy data. However, it is important that these estimates are used thoughtfully when they are transferred to other settings.
13价肺炎球菌结合疫苗（PCV13）已被推荐用于某些成年人群体，并且在许多国家正考虑扩大其使用范围。为了确定现有关于PCV13在成人和老年人中经济评估研究的优势与局限性，开展了一项文献综述。所纳入的大多数研究（10项中的9项）发现，PCV13在成人和/或老年人中具有成本效益。然而，这些结果基于一些并非总能得到有力证据支持的假设。关键的不确定性因素包括PCV13对非侵袭性肺炎的疗效以及儿童疫苗接种计划的群体免疫效应。来自荷兰的关于成人PCV13的新试验证据提供了用经验性疗效数据对未来经济评估进行参数化的能力。然而，当将这些估计值应用于其他情况时，谨慎使用很重要。
